Purpose
To assess the consequences of multiple inhibitors and differential inhibition mechanisms on the prediction of 12 gemfibrozil drug–drug interactions (DDIs). In addition, qualitative zoning of transporter-related gemfibrozil and cyclosporine DDIs was investigated.
Methods
The effect of gemfibrozil and its acyl-glucuronide on different enzymes was incorporated into a metabolic prediction model. The impact of CYP2C8 time-dependent inhibition by gemfibrozil acyl-glucuronide was assessed using repaglinide, cerivastatin, loperamide, rosiglitazone and pioglitazone DDIs. Gemfibrozil and cyclosporine inhibition data obtained in human embryonic kidney cells expressing OATP1B1 and hepatic input concentration ([I]in) were used for qualitative zoning of 14 transporter-mediated DDIs.
Results
Incorporation of time-dependent inhibition by gemfibrozil glucuronide showed no significant improvement in the prediction, as CYP2C8 contributed <65% to the overall elimination of the victim drugs investigated. Qualitative zoning of OATP1B1 DDIs resulted in no false negative predictions; yet the magnitude of observed interactions was significantly over-predicted.
Conclusions
Time-dependent inhibition by gemfibrozil glucuronide is only important for victim drugs eliminated predominantly (>80%) via CYP2C8. Qualitative zoning of OATP1B1 inhibitors based on [I]in/K i is valid in drug screening to avoid false negatives. Refinement of the transporter model by incorporating the fraction of drug transported by a particular transporter is recommended.
Similar content being viewed by others
Abbreviations
- AUC:
-
area under the plasma concentration–time curve
- AUCi:
-
area under the curve in the presence of the inhibitor
- DDI:
-
drug–drug interactions
- fmCYPi :
-
fraction of drug metabolised by the particular P450 enzyme subject to inhibition
- F+, F−:
-
false positive and false negative predictions
- ft:
-
the fraction of drug transported by a particular transporter protein
- [I]:
-
inhibitor concentration
- [I]in:
-
hepatic input concentration
- K I :
-
inhibitor concentration at 50% of k inact
- K i :
-
inhibition constant
- k deg :
-
enzyme degradation rate constant
- k inact :
-
maximal inactivation rate constant
- TDI:
-
time-dependent inhibition
References
G. T. Tucker, J. B. Houston, and S. M. Huang. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential—towards a consensus. Br. J. Clin. Pharmacol. 52(1):107–117 (2001).
K. Ito, H. S. Brown, and J. B. Houston. Database analyses for the prediction of in vivo drug–drug interactions from in vitro data. Br. J. Clin. Pharmacol. 57(4):473–486 (2004).
A. Rostami-Hodjegan and G. Tucker. ‘In silico’ simulations to assess the ‘in vivo’ consequences of ‘in vitro’ metabolic drug–drug interactions. Drug Discov. Today 1(4):441–448 (2004).
Y. H. Wang, D. R. Jones, and S. D. Hall. Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab. Dispos. 32(2):259–266 (2004).
H. S. Brown, K. Ito, A. Galetin, and J. B. Houston. Prediction of in vivo drug–drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. Br. J. Clin. Pharmacol. 60(5):508–518 (2005).
A. Galetin, K. Ito, D. Hallifax, and J. B. Houston. CYP3A4 substrate selection and substitution in the prediction of potential drug–drug interactions. J. Pharmacol. Exp. Ther. 314(1):180–190 (2005).
K. Ito, D. Hallifax, R. S. Obach, and J. B. Houston. Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug–drug interactions: CYP2D6 paradigm. Drug Metab. Dispos. 33(6):837–844 (2005).
A. Galetin, H. Burt, L. Gibbons, and J. B. Houston. Prediction of time-dependent CYP3A4 drug–drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. Drug Metab. Dispos. 34(1):166–175 (2006).
R. S. Obach, R. L. Walsky, K. Venkatakrishnan, E. A. Gaman, J. B. Houston, and L. M. Tremaine. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug–drug interactions. J. Pharmacol. Exp. Ther. 316(1):336–348 (2006).
J. S. Wang, M. Neuvonen, X. Wen, J. T. Backman, and P. J. Neuvonen. Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab. Dispos. 30(12):1352–1356 (2002).
Y. Shitara, M. Hirano, H. Sato and Y. Sugiyama. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug–drug interaction between cerivastatin and gemfibrozil. J. Pharmacol. Exp. Ther. 311(1):228–236 (2004).
L. I. Kajosaari, J. Laitila, P. J. Neuvonen, and J. T. Backman. Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. Basic Clin. Pharmacol. Toxicol. 97(4):249–256 (2005).
X. Wen, J. S. Wang, J. T. Backman, K. T. Kivisto, and P. J. Neuvonen. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. Drug Metab. Dispos. 29(11):1359–1361 (2001).
T. Prueksaritanont, C. Tang, Y. Qiu, L. Mu, R. Subramanian, and J. H. Lin. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab. Dispos. 30(11):1280–1287 (2002).
J. T. Backman, C. Kyrklund, M. Neuvonen, and P. J. Neuvonen. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin. Pharmacol. Ther. 72(6):685–691 (2002).
M. Niemi, J. T. Backman, M. Neuvonen, and P. J. Neuvonen. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia 46(3):347–351 (2003).
D. W. Schneck, B. K. Birmingham, J. A. Zalikowski, P. D. Mitchell, Y. Wang, P. D. Martin, K. C. Lasseter, C. D. Brown, A. S. Windass, and A. Raza. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin. Pharmacol. Ther. 75(5):455–463 (2004).
J. J. Lilja, J. T. Backman, and P. J. Neuvonen. Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects. Br. J. Clin. Pharmacol. 59(4):433–439 (2005).
M. Niemi, P. J. Neuvonen, and K. T. Kivisto. Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride. Clin. Pharmacol. Ther. 70(5):439–445 (2001).
J. T. Backman, H. Luurila, M. Neuvonen, and P. J. Neuvonen. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clin. Pharmacol. Ther. 78(2):154–167 (2005).
B. W. Ogilvie, D. Zhang, W. Li, A. D. Rodrigues, A. E. Gipson, J. Holsapple, P. Toren, and A. Parkinson. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug–drug interactions. Drug Metab. Dispos. 34(1):191–197 (2006).
M. Niemi, J. T. Backman, L. I. Kajosaari, J. B. Leathart, M. Neuvonen, A. K. Daly, M. Eichelbaum, K. T. Kivisto, and P. J. Neuvonen. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin. .Pharmacol. Ther. 77(6):468–478 (2005).
M. Hirano, K. Maeda, Y. Shitara, and Y. Sugiyama. Drug–drug interaction between pitavastatin and various drugs via oatp1b1. Drug Metab. Dispos. 34(7):1229–1236 (2006).
K. Maeda, I. Ieiri, K. Yasuda, A. Fujino, H. Fujiwara, K. Otsubo, M. Hirano, T. Watanabe, Y. Kitamura, K. Kusuhara, and Y. Sugiyama. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clin. Pharmacol. Ther. 79(5):427–439 (2006).
Y. Y. Lau, Y. Huang, L. Frassetto, and L. Z. Benet. Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin. Pharmacol. Ther. 81(2):194–204 (2007).
C. Kyrklund, J. T. Backman, K. T. Kivisto, M. Neuvonen, J. Laitila, and P. J. Neuvonen. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin. Pharmacol. Ther. 69(5):340–345 (2001).
T. Jaakkola, J. T. Backman, M. Neuvonen, and P. J. Neuvonen. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin. Pharmacol. Ther. 77(5):404–14 (2005).
L. J. Deng, F. Wang, and H. D. Li. Effect of gemfibrozil on the pharmacokinetics of pioglitazone. Eur. J. Clin. Pharmacol. 61(11):831–836 (2005).
C. Kyrklund, J. T. Backman, M. Neuvonen, and P. J. Neuvonen. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin. Pharmacol. Ther. 73(6):538–544 (2003).
M. Niemi, J. T. Backman, M. Granfors, J. Laitila, M. Neuvonen, and P. J. Neuvonen. Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. Diabetologia 46(10):1319–1323 (2003).
J. T. Backman, C. Kyrklund, K. T. Kivisto, J. S. Wang, and P. J. Neuvonen. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin. Pharmacol. Ther. 68(2):122–129 (2000).
M. Niemi, A. Tornio, M. K. Pasanen, H. Fredrikson, P. J. Neuvonen, and J. T. Backman. Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide. Eur. J. Clin. Pharmacol. 62:463–472 (2006).
A. Tornio, P. J. Neuvonen, and J. T. Backman. The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone. Eur. J. Clin. Pharmacol. 62:645–651 (2006).
T. Jaakkola, J. Laitila, P. J. Neuvonen, and J. T. Backman. Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors. Basic Clin. Pharmacol. Toxicol. 99:44–51 (2006).
K. A. Kim, J. Chung, D. H. Jung, and J. Y. Park. Identification of cytochrome P450 isoforms involved in the metabolism of loperamide in human liver microsomes. Eur. J. Clin. Pharmacol. 60:575–581 (2004).
F. Ghanbari, K. Rowland-Yeo, J. C. Bloomer, S. E. Clarke, M. S. Lennard, G. T. Tucker, and A. Rostami-Hodjegan. A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro–in vivo extrapolation. Curr. Drug Metab. 7(3):315–334 (2006).
N. J. Hassan, D. J. Pountney, C. Ellis, D. E. Mossakowska. BacMam recombinant baculovirus in transporter expression: a study of BCRP and OATP1B1. Protein Expr. Purif. 47(2):591–8 (2006).
L. Sabordo, B. C. Sallustio, A. M. Evans, and R. L. Nation. Hepatic disposition of the acyl glucuronide1-O-gemfibrozil-beta-d-glucuronide: effects of dibromosulfophthalein on membrane transport and aglycone formation. J. Pharmacol. Exp. Ther. 288(2):414–420 (1999).
T. D. Bjornsson, J. T. Callaghan, H. J. Einolf, V. Fischer, L. Gan, S. Grimm, J. Kao, S. P. King, G. Miwa, L. Ni, G. Kumar, J. McLeod, R. S. Obach, S. Roberts, A. Roe, A. Shah, F. Snikeris, J. T. Sullivan, D. Tweedie, J. M. Vega, J. Walsh, and S. A. Wrighton. The conduct of in vitro and in vivo drug–drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab. Dispos. 31(7):815–832 (2003).
P. Mathew, T. Cuddy, W. G. Tracewell, and D. Salazar. An open-label study on the pharmacokinetics (PK) of pitavastatin (NK-104) when administered concomitantly with fenofibrate or gemfibrozil in healthy volunteers. Clin. Pharmacol. Ther. 75:P33–P33 (2004).
C. Olbricht, C. Wanner, T. Eisenhauer, V. Kliem, R. Doll, M. Boddaert, P. O’Grady, M. Krekler, B. Mangold, and U. Christians. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. Clin. Pharmacol. Ther. 62(3):311–321 (1997).
A. Asberg, A. Hartmann, E. Fjeldsa, S. Bergan, and H. Holdaas. Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients. Am. J. Transplant. 1(4):382–6 (2001).
S. G. Simonson, A. Raza, P. D. Martin, P. D. Mitchell, J. A. Jarcho, C. D. Brown, A. S. Windass, and D. W. Schneck. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin. Pharmacol. Ther. 76(2):167–177 (2004).
T. Hasunuma, M. Nakamura, T. Yachi, N. Arisawa, K. Fukushima, H. Iijima. The drug–drug interactions of pitavastatin (NK-104), a novel HMG-CoA reductase inhibitor and cyclosporine. J. Clin. Ther. Med. 19:381–389 (2003).
W. Muck, I. Mai, L. Fritsche, K. Ochmann, G. Rohde, S. Unger, A. Johne, S. Bauer, K. Budde, I. Roots, H. H. Neumayer, and J. Kuhlmann. Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients. Clin. Pharmacol. Ther. 65(3):251–61 (1999).
L. I. Kajosaari, M. Niemi, M. Neuvonen, J. Laitila, P. J. Neuvonen, and J. T. Backman. Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin. Pharmacol. Ther. 78(4):388–399 (2005).
D. W. Everett, T. J. Chando, G. C. Didonato, S. M. Singhvi, H. Y. Pan, and S. H. Weinstein. Biotransformation of pravastatin sodium in humans. Drug Metab. Dispos. 19(4):740–748 (1991).
Y. Kameyama, K. Yamashita, K. Kobayashi, M. Hosokawa, and K. Chiba. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet. Genomics 15(7):513–522 (2005).
Y. Y. Lau, H. Okochi, Y. Huang, and L. Z. Benet. Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems. J. Pharmacol. Exp. Ther. 316(2):762–771 (2006).
R. H. Ho, R. G. Tirona, B. F. Leake, H. Glaeser, W. Lee, C. J. Lemke, Y. Wang, and R. B. Kim. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression and pharmacogenetics. Gastroenterology 130:1793–1806 (2006).
Y. Shitara and Y. Sugiyama. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug–drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol. Ther. 112(1):71–105 (2006).
T. M. Polasek, D. J. Elliot, B. C. Lewis, and J. O. Miners. Mechanism-based inactivation of human cytochrome P450 by drugs in vitro. J. Pharmacol. Exp. Ther. 311(3):996–1007 (2004).
M. Hirano, K. Maeda, Y. Shitara, and Y. Sugiyama. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J. Pharmacol. Exp. Ther. 311(1):139–146 (2004).
N. Isoherranen, K. L. Kunze, K. E. Allen, W. L. Nelson, and K. E. Thummel. Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab. Dispos. 32:1121–1131 (2004).
J. Y. Chien, A. Lucksiri, C. S. Ernest, II, C. Gorski, S. A. Wrighton, and S. D. Hall. Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole. Drug Metab. Dispos. 34(7):1208–1219 (2006).
H. Lennernas. Clinical pharmacokinetics of atorvastatin. Clin. Pharmacokinet. 42:1141–1160 (2003).
S. M. Huang, R. Temple, D. C. Throckmorton, and L. J. Lesko. Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin. Pharmacol. Ther. 81(2):298–304 (2007).
Y. Shitara, T. Horie, and Y. Sugiyama. Transporters as a determinant of drug clearance and tissue distribution. Eur. J. Pharm. Sci. 27(5):425–446 (2006).
I. Ieiri, S. Suwannakul, K. Maeda, H. Uchimaru, K. Hashimoto, M. Kimura, H. Fujino, M. Hirano, H. Kusuhara, S. Irie, S. Higuchi, and Y. Sugiyama. SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. Clin. Pharmacol. Ther. In press (2007)
K. T. Kivisto and M. Niemi. Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharm. Res. 24(2):239–47 (2007).
K. S. Pang and J. R. Gillette. Kinetics of metabolite formation and elimination in the perfused rat liver preparation: differences between the elimination of preformed acetaminophen and acetaminophen formed from phenacetin. J. Pharmacol. Exp. Ther. 207(1):178–194 (1978).
L. Liu and K. S. Pang. The roles of transporters and enzymes in hepatic drug processing. Drug Metab. Dispos. 33(1):1–9 (2005).
Acknowledgement
The authors would like to thank Dr Kathryn Kenworthy and Mrs Jennifer Thomas (GlaxoSmithKline, Ware, UK) for their help with the OATP1B1 inhibition assay.
The work was funded by a consortium of pharmaceutical companies (GlaxoSmithKline, Lilly, Novartis, Pfizer and Servier) within the Centre for Applied Pharmacokinetic Research at the University of Manchester. Part of this study was presented at the 9th ISSX Meeting, June 4–7, 2006, Manchester, UK.
Author information
Authors and Affiliations
Corresponding author
Appendix
Appendix
Total hepatic clearance can be described by Eq. 7 (58,61,62):
where PSinflux and PSefflux are the membrane permeability–surface area products of a drug across the sinusoidal membrane, for the influx and efflux processes, respectively, and CLint is the intrinsic clearance representing both metabolic and biliary excretion of the drug. When PSefflux << CLint, CLint,all = PSinflux. PSinflux can also be described as the clearance due to influx into the cell (CLinflux) (62).
When the uptake of a drug involves more than one transporter, the total influx clearance can be defined as the sum of the ratios of the Michaelis–Menten parameters for the individual transporters, assuming linear kinetics (substrate concentration <<K m), as shown in Eq. 8:
where 1 and 2 refer to influx via a particular transporter (e.g., OATP1B1). The term ftOATP1B1 refers to the fraction of the drug transported by way of the OATP1B1 transporter, whereas the remaining fraction is transported by unspecified routes.
Influx clearance in the presence of a competitive inhibitor of OATP1B1 (CLinflux i ) or 2 inhibitors acting via the same mechanism is shown in Eqs. 9 and 10, respectively:
Combining Eqs. 8 and 10 gives:
Assuming competitive inhibition and that the other transport processes are unaffected by the inhibitor, the AUC ratio is given by the following equation:
Rights and permissions
About this article
Cite this article
Hinton, L.K., Galetin, A. & Houston, J.B. Multiple Inhibition Mechanisms and Prediction of Drug–Drug Interactions: Status of Metabolism and Transporter Models as Exemplified by Gemfibrozil–Drug Interactions. Pharm Res 25, 1063–1074 (2008). https://doi.org/10.1007/s11095-007-9446-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11095-007-9446-6